Referencias

Bakhle, D. S. M., Pune, IN), Shah, Chirag Anilkumar (Maharashtra, Pune, IN),
Gadve, Snehal Ameet (Maharashtra, Pune, IN), Sharma, Neha
(Maharashtra, Pune, IN), Chandran, Sajeev (Maharashtra, Pune, IN),
Deshmukh, Ashish Ashokrao (Maharashtra, Pune, IN). (2016). United
States Patent No. 20160008335.
Dependence, A. FDA Issues Public Health Advisory for Antipsychotic Agents.
Donohue, M. C., Moghadam, S. H., Roe, A. D., Sun, C. K., Edland, S. D., Thomas,
R. G., Rissman, R. A. (2015). Longitudinal plasma amyloid beta in
Alzheimer's disease clinical trials. Alzheimers & Dementia, 11(9), 10691079. doi:10.1016/j.jalz.2014.07.156
Homma, Akira, et al. "Efficacy and Safety of Sustained Release Donepezil High
Dose versus Immediate Release Donepezil Standard Dose in Japanese
Patients with Severe Alzheimers Disease: A Randomized, Double-Blind
Trial." Journal of Alzheimer's Disease Preprint (2016): 1-13.Inoue, J.,
Hoshino, R., Nojima, H., Ishida, W., & Okamoto, N. (2010). Investigation of
responders and non-responders to long-term donepezil treatment.
Psychogeriatrics, 10(2), 53-61. doi:10.1111/j.1479-8301.2010.00319.x
Luan, J. J., Mani, R., & Hung, H. M. J. (2016). Comparison of Treatment Effects
Between US and Non-US Study Sites in Multiregional Alzheimer Disease
Clinical Trials. Therapeutic Innovation & Regulatory Science, 50(1), 66-73.
doi:10.1177/2168479015611629.
Unzeta, M., Esteban, G., Bolea, I., Fogel, W. A., RAMSAY, R. R., Youdim, M. B., &
Marco-Contelles, J. (2016). Multi-target directed donepezil-like ligands for
Alzheimer's disease. Frontiers in Neuroscience, 10, 205.
(2005). Product Update. Journal of Psychosocial Nursery and Mental Health
Services. 43(7) 12, 51. doi: 10.3928/02793695-20050701-02